Copyright Reports & Markets. All rights reserved.

Global Gastric Cancer Therapy Market Research Report 2022

Buy now

1 Gastric Cancer Therapy Market Overview

  • 1.1 Product Overview and Scope of Gastric Cancer Therapy
  • 1.2 Gastric Cancer Therapy Segment by Type
  • 1.2.1 Global Gastric Cancer Therapy Sales Growth Rate Comparison by Type (2022-2028)
  • 1.2.2 Prescription Drugs
  • 1.2.3 Non-Prescription Drugs
  • 1.3 Gastric Cancer Therapy Segment by Application
  • 1.3.1 Global Gastric Cancer Therapy Sales Comparison by Application: (2022-2028)
  • 1.3.2 Online Sales
  • 1.3.3 Offline Sales
  • 1.4 Global Gastric Cancer Therapy Market Size Estimates and Forecasts
  • 1.4.1 Global Gastric Cancer Therapy Revenue 2017-2028
  • 1.4.2 Global Gastric Cancer Therapy Sales 2017-2028
  • 1.4.3 Gastric Cancer Therapy Market Size by Region: 2017 Versus 2021 Versus 2028
  • 2 Gastric Cancer Therapy Market Competition by Manufacturers

    • 2.1 Global Gastric Cancer Therapy Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Gastric Cancer Therapy Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Gastric Cancer Therapy Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Gastric Cancer Therapy Manufacturing Sites, Area Served, Product Type
    • 2.5 Gastric Cancer Therapy Market Competitive Situation and Trends
    • 2.5.1 Gastric Cancer Therapy Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Gastric Cancer Therapy Players Market Share by Revenue
  • 2.5.3 Global Gastric Cancer Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
  • 3 Gastric Cancer Therapy Retrospective Market Scenario by Region

    • 3.1 Global Gastric Cancer Therapy Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Gastric Cancer Therapy Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Gastric Cancer Therapy Market Facts & Figures by Country
    • 3.3.1 North America Gastric Cancer Therapy Sales by Country
  • 3.3.2 North America Gastric Cancer Therapy Revenue by Country
  • 3.3.3 United States
  • 3.3.4 Canada
  • 3.4 Europe Gastric Cancer Therapy Market Facts & Figures by Country
  • 3.4.1 Europe Gastric Cancer Therapy Sales by Country
  • 3.4.2 Europe Gastric Cancer Therapy Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
  • 3.5 Asia Pacific Gastric Cancer Therapy Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Gastric Cancer Therapy Sales by Region
  • 3.5.2 Asia Pacific Gastric Cancer Therapy Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 China Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.6 Latin America Gastric Cancer Therapy Market Facts & Figures by Country
  • 3.6.1 Latin America Gastric Cancer Therapy Sales by Country
  • 3.6.2 Latin America Gastric Cancer Therapy Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
  • 3.6.6 Colombia
  • 3.7 Middle East and Africa Gastric Cancer Therapy Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Gastric Cancer Therapy Sales by Country
  • 3.7.2 Middle East and Africa Gastric Cancer Therapy Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE
  • 4 Global Gastric Cancer Therapy Historic Market Analysis by Type

    • 4.1 Global Gastric Cancer Therapy Sales Market Share by Type (2017-2022)
    • 4.2 Global Gastric Cancer Therapy Revenue Market Share by Type (2017-2022)
    • 4.3 Global Gastric Cancer Therapy Price by Type (2017-2022)

    5 Global Gastric Cancer Therapy Historic Market Analysis by Application

    • 5.1 Global Gastric Cancer Therapy Sales Market Share by Application (2017-2022)
    • 5.2 Global Gastric Cancer Therapy Revenue Market Share by Application (2017-2022)
    • 5.3 Global Gastric Cancer Therapy Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Novartis AG
    • 6.1.1 Novartis AG Corporation Information
  • 6.1.2 Novartis AG Description and Business Overview
  • 6.1.3 Novartis AG Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.1.4 Novartis AG Gastric Cancer Therapy Product Portfolio
  • 6.1.5 Novartis AG Recent Developments/Updates
  • 6.2 Glaxo SmithKline Plc
  • 6.2.1 Glaxo SmithKline Plc Corporation Information
  • 6.2.2 Glaxo SmithKline Plc Description and Business Overview
  • 6.2.3 Glaxo SmithKline Plc Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.2.4 Glaxo SmithKline Plc Gastric Cancer Therapy Product Portfolio
  • 6.2.5 Glaxo SmithKline Plc Recent Developments/Updates
  • 6.3 Roche Holding Limited
  • 6.3.1 Roche Holding Limited Corporation Information
  • 6.3.2 Roche Holding Limited Description and Business Overview
  • 6.3.3 Roche Holding Limited Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.3.4 Roche Holding Limited Gastric Cancer Therapy Product Portfolio
  • 6.3.5 Roche Holding Limited Recent Developments/Updates
  • 6.4 AptarGroup Incorporated
  • 6.4.1 AptarGroup Incorporated Corporation Information
  • 6.4.2 AptarGroup Incorporated Description and Business Overview
  • 6.4.3 AptarGroup Incorporated Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.4.4 AptarGroup Incorporated Gastric Cancer Therapy Product Portfolio
  • 6.4.5 AptarGroup Incorporated Recent Developments/Updates
  • 6.5 Squibb Company
  • 6.5.1 Squibb Company Corporation Information
  • 6.5.2 Squibb Company Description and Business Overview
  • 6.5.3 Squibb Company Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.5.4 Squibb Company Gastric Cancer Therapy Product Portfolio
  • 6.5.5 Squibb Company Recent Developments/Updates
  • 6.6 Boston Scientific Corporation
  • 6.6.1 Boston Scientific Corporation Corporation Information
  • 6.6.2 Boston Scientific Corporation Description and Business Overview
  • 6.6.3 Boston Scientific Corporation Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.6.4 Boston Scientific Corporation Gastric Cancer Therapy Product Portfolio
  • 6.6.5 Boston Scientific Corporation Recent Developments/Updates
  • 6.7 Pfizer.
  • 6.6.1 Pfizer. Corporation Information
  • 6.6.2 Pfizer. Description and Business Overview
  • 6.6.3 Pfizer. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.4.4 Pfizer. Gastric Cancer Therapy Product Portfolio
  • 6.7.5 Pfizer. Recent Developments/Updates
  • 6.8 Agilent Technologies, Inc.
  • 6.8.1 Agilent Technologies, Inc. Corporation Information
  • 6.8.2 Agilent Technologies, Inc. Description and Business Overview
  • 6.8.3 Agilent Technologies, Inc. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.8.4 Agilent Technologies, Inc. Gastric Cancer Therapy Product Portfolio
  • 6.8.5 Agilent Technologies, Inc. Recent Developments/Updates
  • 6.9 Illumina, Inc.
  • 6.9.1 Illumina, Inc. Corporation Information
  • 6.9.2 Illumina, Inc. Description and Business Overview
  • 6.9.3 Illumina, Inc. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.9.4 Illumina, Inc. Gastric Cancer Therapy Product Portfolio
  • 6.9.5 Illumina, Inc. Recent Developments/Updates
  • 6.10 Thermo Fisher Scientific, Inc.
  • 6.10.1 Thermo Fisher Scientific, Inc. Corporation Information
  • 6.10.2 Thermo Fisher Scientific, Inc. Description and Business Overview
  • 6.10.3 Thermo Fisher Scientific, Inc. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.10.4 Thermo Fisher Scientific, Inc. Gastric Cancer Therapy Product Portfolio
  • 6.10.5 Thermo Fisher Scientific, Inc. Recent Developments/Updates
  • 6.11 General Electric Company
  • 6.11.1 General Electric Company Corporation Information
  • 6.11.2 General Electric Company Gastric Cancer Therapy Description and Business Overview
  • 6.11.3 General Electric Company Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.11.4 General Electric Company Gastric Cancer Therapy Product Portfolio
  • 6.11.5 General Electric Company Recent Developments/Updates
  • 6.12 BD
  • 6.12.1 BD Corporation Information
  • 6.12.2 BD Gastric Cancer Therapy Description and Business Overview
  • 6.12.3 BD Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.12.4 BD Gastric Cancer Therapy Product Portfolio
  • 6.12.5 BD Recent Developments/Updates
  • 6.13 Abbott
  • 6.13.1 Abbott Corporation Information
  • 6.13.2 Abbott Gastric Cancer Therapy Description and Business Overview
  • 6.13.3 Abbott Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.13.4 Abbott Gastric Cancer Therapy Product Portfolio
  • 6.13.5 Abbott Recent Developments/Updates
  • 6.14 QIAGEN
  • 6.14.1 QIAGEN Corporation Information
  • 6.14.2 QIAGEN Gastric Cancer Therapy Description and Business Overview
  • 6.14.3 QIAGEN Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.14.4 QIAGEN Gastric Cancer Therapy Product Portfolio
  • 6.14.5 QIAGEN Recent Developments/Updates
  • 6.15 Siemens Healthcare GmbH
  • 6.15.1 Siemens Healthcare GmbH Corporation Information
  • 6.15.2 Siemens Healthcare GmbH Gastric Cancer Therapy Description and Business Overview
  • 6.15.3 Siemens Healthcare GmbH Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.15.4 Siemens Healthcare GmbH Gastric Cancer Therapy Product Portfolio
  • 6.15.5 Siemens Healthcare GmbH Recent Developments/Updates
  • 6.16 F. Hoffmann-La Roche Ltd.
  • 6.16.1 F. Hoffmann-La Roche Ltd. Corporation Information
  • 6.16.2 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Description and Business Overview
  • 6.16.3 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.16.4 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Product Portfolio
  • 6.16.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
  • 6.17 Koninklijke Philips N.V.
  • 6.17.1 Koninklijke Philips N.V. Corporation Information
  • 6.17.2 Koninklijke Philips N.V. Gastric Cancer Therapy Description and Business Overview
  • 6.17.3 Koninklijke Philips N.V. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.17.4 Koninklijke Philips N.V. Gastric Cancer Therapy Product Portfolio
  • 6.17.5 Koninklijke Philips N.V. Recent Developments/Updates
  • 6.18 Eli Lilly and Company
  • 6.18.1 Eli Lilly and Company Corporation Information
  • 6.18.2 Eli Lilly and Company Gastric Cancer Therapy Description and Business Overview
  • 6.18.3 Eli Lilly and Company Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.18.4 Eli Lilly and Company Gastric Cancer Therapy Product Portfolio
  • 6.18.5 Eli Lilly and Company Recent Developments/Updates
  • 6.19 F. Hoffmann-La Roche Ltd.
  • 6.19.1 F. Hoffmann-La Roche Ltd. Corporation Information
  • 6.19.2 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Description and Business Overview
  • 6.19.3 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.19.4 F. Hoffmann-La Roche Ltd. Gastric Cancer Therapy Product Portfolio
  • 6.19.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
  • 6.20 Merck KGaA
  • 6.20.1 Merck KGaA Corporation Information
  • 6.20.2 Merck KGaA Gastric Cancer Therapy Description and Business Overview
  • 6.20.3 Merck KGaA Gastric Cancer Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.20.4 Merck KGaA Gastric Cancer Therapy Product Portfolio
  • 6.20.5 Merck KGaA Recent Developments/Updates
  • 7 Gastric Cancer Therapy Manufacturing Cost Analysis

    • 7.1 Gastric Cancer Therapy Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Gastric Cancer Therapy
  • 7.4 Gastric Cancer Therapy Industrial Chain Analysis
  • 8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Gastric Cancer Therapy Distributors List
    • 8.3 Gastric Cancer Therapy Customers

    9 Gastric Cancer Therapy Market Dynamics

    • 9.1 Gastric Cancer Therapy Industry Trends
    • 9.2 Gastric Cancer Therapy Market Drivers
    • 9.3 Gastric Cancer Therapy Market Challenges
    • 9.4 Gastric Cancer Therapy Market Restraints

    10 Global Market Forecast

    • 10.1 Gastric Cancer Therapy Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Gastric Cancer Therapy by Type (2023-2028)
  • 10.1.2 Global Forecasted Revenue of Gastric Cancer Therapy by Type (2023-2028)
  • 10.2 Gastric Cancer Therapy Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Gastric Cancer Therapy by Application (2023-2028)
  • 10.2.2 Global Forecasted Revenue of Gastric Cancer Therapy by Application (2023-2028)
  • 10.3 Gastric Cancer Therapy Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Gastric Cancer Therapy by Region (2023-2028)
  • 10.3.2 Global Forecasted Revenue of Gastric Cancer Therapy by Region (2023-2028)
  • 11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
    • 12.1.2 Market Size Estimation
    • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
    • 12.2.1 Secondary Sources
    • 12.2.2 Primary Sources
    • 12.3 Author List
    • Gastric Cancer Therapy is caused by uncontrolled abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as Gastric Cancer Therapy or stomach cancer. Diet and stomach disorders are both risk factors for Gastric Cancer Therapy. Stomach pain, poor appetite, weight loss, indigestions, nausea, vomiting with or without blood are some of the symptoms of Gastric Cancer Therapy.
      Industry Insights

      Due to the COVID-19 pandemic, the global Gastric Cancer Therapy market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Gastric Cancer Therapy market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Gastric Cancer Therapy landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

      Prescription Drugs accounting for % of the Gastric Cancer Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Online Sales segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

      The global major manufacturers of Gastric Cancer Therapy include Novartis AG, Glaxo SmithKline Plc, Roche Holding Limited, AptarGroup Incorporated, Squibb Company, Boston Scientific Corporation, Pfizer., Agilent Technologies, Inc. and Illumina, Inc., etc. In terms of revenue, the global 3 largest players have a % market share of Gastric Cancer Therapy in 2021.

      This report focuses on Gastric Cancer Therapy volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Gastric Cancer Therapy market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

      Key Drivers & Barriers

      High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

      Post-covid-19 Outlook

      The readers in the section will understand how the Gastric Cancer Therapy market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

      Segmental Outlook

      Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

      Segment by Type

      Prescription Drugs

      Non-Prescription Drugs

      Segment by Application

      Online Sales

      Offline Sales

      Regional Outlook

      This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

      North America

      United States

      Canada

      Europe

      Germany

      France

      U.K.

      Italy

      Russia

      Asia-Pacific

      China

      Japan

      South Korea

      India

      Australia

      China Taiwan

      Indonesia

      Thailand

      Malaysia

      Latin America

      Mexico

      Brazil

      Argentina

      Colombia

      Middle East & Africa

      Turkey

      Saudi Arabia

      UAE

      Competitive Scenario

      In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

      Novartis AG

      Glaxo SmithKline Plc

      Roche Holding Limited

      AptarGroup Incorporated

      Squibb Company

      Boston Scientific Corporation

      Pfizer.

      Agilent Technologies, Inc.

      Illumina, Inc.

      Thermo Fisher Scientific, Inc.

      General Electric Company

      BD

      Abbott

      QIAGEN

      Siemens Healthcare GmbH

      F. Hoffmann-La Roche Ltd.

      Koninklijke Philips N.V.

      Eli Lilly and Company

      F. Hoffmann-La Roche Ltd.

      Merck KGaA

      Frequently Asked Questions

      Which product segment grabbed the largest share in the Gastric Cancer Therapy market?

      How is the competitive scenario of the Gastric Cancer Therapy market?

      Which are the key factors aiding the Gastric Cancer Therapy market growth?

      Which are the prominent players in the Gastric Cancer Therapy market?

      Which region holds the maximum share in the Gastric Cancer Therapy market?

      What will be the CAGR of the Gastric Cancer Therapy market during the forecast period?

      Which application segment emerged as the leading segment in the Gastric Cancer Therapy market?

      What key trends are likely to emerge in the Gastric Cancer Therapy market in the coming years?

      What will be the Gastric Cancer Therapy market size by 2028?

      Which company held the largest share in the Gastric Cancer Therapy market?

      Buy now